NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.25383036046286,3.4253149529314095,26.104852571896974,1.4167212448598,0.122016065451132,1.07274845752393,log2_fold_induction,2,0.366048196353396,,1.12416317094731,1.12416317094731,0.691163906754019,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,63.282663291588,2.185870494709979,20.56191575675956,1.31306357549003,9.65026114229828,55.1280543709385,percent_activity,2,28.9507834268948,,1.25092321823579,1.25092321823579,0.512156471094901,20,cell cycle
APR_HepG2_CellCycleArrest_24h_up,"Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",, , , ,,,Active,0.954745127797922,1.3549301552437099,12.183160629624616,1.08575997022954,0.070464527201123,0.795620940290305,log2_fold_induction,1.69897000433602,0.70464527201123,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.36294892290625,0.749267411962775,0.497783296693514,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.18723573540609,1.3379122620136514,53.214554928840556,1.72603043418871,0.0887379366431112,0.94376227797899,log2_fold_induction,2.30102999566398,0.887379366431112,"[""Borderline active"",""Borderline active""]",2.24119917794371,1.13668711244693,0.682736636536323,20,cell cycle
APR_HepG2_MitoMembPot_24h_dn,"Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,7.28499425921531,8.769200591006673,112.26724861358926,2.05025307931652,0.0830747818300165,6.07082854935635,log2_fold_induction,2.30102999566398,0.830747818300165,,1.71683243255007,1.5069992099548,1.6929163641209,20,cell morphology
APR_HepG2_MitoMembPot_72h_dn,"Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,1.92955308220034,2.648105713382579,121.48565464699529,2.08452499830083,0.0728654098833392,1.60796090183772,log2_fold_induction,2.30102999566398,0.728654098833392,,2.01528487289684,1.79937760272846,1.7800253727526,20,cell morphology
ATG_BRE_CIS_up,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.",NP_005891.1,SMAD1,SMAD family member 1,https://www.ncbi.nlm.nih.gov/gene/4086,,,Active,1.7636818554806128,1.9258045784898372,45.4641273603395,1.6576688596435538,0.183163117917566,1.5509006646475232,log2_fold_induction,2.30102999566398,0.91581558958783,,1.6844407390478904,1.3823364612818894,0.8946357132198687,20,dna binding
ATG_CAR_TRANS_up,"Data from the assay component ATG_CAR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CAR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001070948.1,NR1I3,"nuclear receptor subfamily 1, group I, member 3",https://www.ncbi.nlm.nih.gov/gene/9970,"[8,107,58,8,107,58]","[456,715]",Active,1.2418881781596185,1.2314403776944818,11.706103037375204,1.0684123424645227,0.20169684227582294,1.0349068151542178,log2_fold_induction,1.84509804001426,1.0084842113791146,"[""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.9023652882634348,1.0393073521131564,-0.18369959289660165,20,nuclear receptor
ATG_chAR_XSP2_dn,ATG_chAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/422165,,,Active,1.8289536568571256,2.8995872085107184,18.698076355636296,1.2717969289373041,0.21025448628099835,1.667212609021676,log2_fold_induction,2.30102999566398,0.6307634588429951,,0.9704231434621937,0.9704231434621937,0.2397705694739385,20,nuclear receptor
ATG_chERa_XSP2_up,"The assay endpoint ATG_chERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/396099,,,Active,2.301819759991475,2.9791570620977623,9.222616528165197,0.9648541512633751,0.2575470971611746,2.3730548810664214,log2_fold_induction,2.30102999566398,0.7726412914835237,,0.6711048020786801,0.6711048020786801,0.01940127091838717,20,nuclear receptor
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,2.589352235308062,2.342980531556642,10.351973528924708,1.0150231527897886,0.22103062321117403,2.819555160117539,log2_fold_induction,1.84509804001426,1.10515311605587,,0.9465169744149459,0.7672827791321459,0.5045862665235149,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.862815916512699,3.686477476339492,14.808903382152726,1.1705228996614492,0.10106210757931403,1.8201471236280786,log2_fold_induction,2.30102999566398,0.5053105378965701,,0.8379626727235956,0.6193502720646742,0.43111114562568065,20,nuclear receptor
ATG_frAR_XSP2_dn,ATG_frAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,ar.L,androgen receptor L homeolog,https://www.ncbi.nlm.nih.gov/gene/399456,,,Active,1.602101102433536,2.8024174010985408,4.352719257469823,0.6387606568510404,0.1905617987534044,1.6456006502166243,log2_fold_induction,1.84509804001426,0.5716853962602132,,0.48662942804685805,0.48662942804685805,0.07136945979046738,20,nuclear receptor
ATG_frER1_XSP2_up,"The assay endpoint ATG_frER1_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr1.L,estrogen receptor 1 L homeolog,https://www.ncbi.nlm.nih.gov/gene/398734,,,Active,2.2188095813171147,2.932072381721807,12.606422535011838,1.1005918594728197,0.25224588532771924,2.0670551055807547,log2_fold_induction,2.30102999566398,0.7567376559831578,,0.7521428099851291,0.7521428099851291,-0.06191758608007891,20,nuclear receptor
ATG_frER2_XSP2_up,"The assay endpoint ATG_frER2_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2.L,estrogen receptor 2 L homeolog,https://www.ncbi.nlm.nih.gov/gene/100174814,,,Active,1.7245528003328383,3.363628868845961,3.5115909853895735,0.5455039254764152,0.17090200966241173,1.9533385612358756,log2_fold_induction,1.84509804001426,0.5127060289872352,,0.4988065147563435,0.4988065147563435,0.42622361178284957,20,nuclear receptor
ATG_hAR_XSP2_dn,ATG_hAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.1252222558125462,1.6593075961188093,3.0754861486840785,0.4879137753969579,0.2260425289127603,1.3917039015954162,log2_fold_induction,1.30102999566398,0.6781275867382809,,0.5735547812926878,0.5735547812926878,0.03618959867332211,20,nuclear receptor
ATG_hERa_XSP2_up,"The assay endpoint ATG_hERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,2.169243548147122,3.4697518293230964,11.61215516769886,1.0649128304687252,0.20839564853166204,2.035757735955027,log2_fold_induction,2.30102999566398,0.6251869455949861,,0.6261196773386639,0.6261196773386639,-0.0014606413405442442,20,nuclear receptor
ATG_hERb_XSP2_up,"The assay endpoint ATG_hERb_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,1.2888969926662162,1.5635880031962885,5.056898878660228,0.7038842692586162,0.2747733610199642,1.24816446198499,log2_fold_induction,1.84509804001426,0.8243200830598926,"[""Hit-call potentially confounded by overfitting""]",0.9241608780009162,0.9241608780009162,-0.1401519195694635,20,nuclear receptor
ATG_hPPARg_XSP2_up,"The assay endpoint ATG_hPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,,,Active,1.2165067471124762,1.9704200393176043,20.025814647892993,1.3015901921664281,0.20579482594884976,1.239327832240221,log2_fold_induction,1.84509804001426,0.6173844778465493,,1.3032202228266792,1.3032202228266792,1.1823098649622887,20,nuclear receptor
ATG_mPPARg_XSP2_up,"The assay endpoint ATG_mPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",,Pparg,peroxisome proliferator activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/19016,,,Active,1.3344939609677378,2.5495947432414643,18.60990677647609,1.2697441976034471,0.17447138275671079,1.3484979220764433,log2_fold_induction,2.30102999566398,0.5234141482701323,,1.2459669307420698,1.2459669307420698,1.1504638836389818,20,nuclear receptor
ATG_mPXR_XSP2_up,"The assay endpoint ATG_mPXR_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,,,Active,0.9229073936086829,1.7061789789481,3.812203973048697,0.5811761296366975,0.18030687381884508,1.1148344025769248,log2_fold_induction,1.84509804001426,0.5409206214565352,"[""Hit-call potentially confounded by overfitting""]",0.6998017493774147,0.6998017493774147,-0.16805409480263278,20,nuclear receptor
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,1.0492420162202079,1.3510914158153455,18.51257792747474,1.2674668996670657,0.15531769411576343,1.135014531950753,log2_fold_induction,1.84509804001426,0.7765884705788172,,1.3651313429144436,1.2465105324444126,1.0624521460811291,20,dna binding
ATG_PPARg_TRANS_up,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,"[72,36,58,34,163,34,36,58,72,163]",,Active,2.2579567703668664,1.96777797049784,27.83638474260619,1.4446128304970713,0.2294930428350727,1.881630643206781,log2_fold_induction,1.84509804001426,1.1474652141753636,"[""Hit-call potentially confounded by overfitting""]",1.4517343404503125,1.265444765719982,0.9668625832603277,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,2.001402876481884,3.0032829001348453,17.201035568774834,1.2355545938997683,0.13328100901796647,1.8383346181761526,log2_fold_induction,1.84509804001426,0.6664050450898323,,1.0606200300283581,0.8861671916754412,0.6823341600978254,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,1.823095027555268,1.4153930305450677,10.298286176872514,1.0127649561753973,0.2576097222766731,1.817167160893424,log2_fold_induction,2.30102999566398,1.2880486113833656,,1.1606787054710863,0.9611205696410604,0.6428291867670468,20,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1,RXRB,"retinoid X receptor, beta",https://www.ncbi.nlm.nih.gov/gene/6257,,,Active,1.382767583357188,1.3919602326480256,4.77056749158793,0.6785700444081694,0.19867917932204862,1.5159457883324232,log2_fold_induction,2.30102999566398,0.9933958966102431,,1.1150950001381115,0.5491957935243504,-0.34550489971852627,20,nuclear receptor
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2,SP1,Sp1 transcription factor,https://www.ncbi.nlm.nih.gov/gene/6667,"[148,148]",,Active,0.6233938669620029,1.186520564889385,46.80574657328321,1.670299176831719,0.10507931938290839,0.610005965997167,log2_fold_induction,2.30102999566398,0.525396596914542,"[""Borderline active""]",1.953771493359958,1.6741349221735167,1.299380149811617,20,dna binding
ATG_trAR_XSP2_dn,ATG_trAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/101947425,,,Active,1.5072982605982013,2.433729985786126,4.784915902333233,0.6798743092030246,0.2064455615319386,1.578866623776568,log2_fold_induction,1.30102999566398,0.6193366845958158,"[""Hit-call potentially confounded by overfitting""]",0.6059393383060565,0.6059393383060565,0.22896947910539328,20,nuclear receptor
ATG_trERa_XSP2_up,"The assay endpoint ATG_trERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/101933533,,,Active,2.5613564508189937,2.8466564977660487,7.6216000802432395,0.8820461567819603,0.29992571435167914,2.338823108516084,log2_fold_induction,1.84509804001426,0.8997771430550374,"[""Hit-call potentially confounded by overfitting""]",0.6183423279138239,0.6183423279138239,-0.06258791356583338,20,nuclear receptor
ATG_zfAR_XSP2_dn,ATG_zfAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,ar,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/100005148,,,Active,0.8673659550634405,1.053284320902325,14.120748515399221,1.1498577184928034,0.2744956696720431,0.919742137570711,log2_fold_induction,1.84509804001426,0.8234870090161293,"[""Borderline active"",""Only one conc above baseline, active""]",1.7176760635556214,1.7176760635556214,0.7243542143660413,20,nuclear receptor
ATG_zfER2a_XSP2_up,"The assay endpoint ATG_zfER2a_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2a,estrogen receptor 2a,https://www.ncbi.nlm.nih.gov/gene/317734,,,Active,1.0311406398717855,1.8142857354553088,17.178678238781217,1.234989745310894,0.1894484093144628,1.019659473714854,log2_fold_induction,2.30102999566398,0.5683452279433884,,1.280621021132736,1.280621021132736,0.7469629058684029,20,nuclear receptor
ATG_zfER2b_XSP2_up,"The assay endpoint ATG_zfER2b_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2b,estrogen receptor 2b,https://www.ncbi.nlm.nih.gov/gene/317733,,,Active,4.261543228295733,8.190811236869859,22.91629905150707,1.3601444810401293,0.17342780444477252,4.351239371490758,log2_fold_induction,1.84509804001426,0.5202834133343175,"[""Hit-call potentially confounded by overfitting""]",1.226741151681071,1.226741151681071,1.2115655675352015,20,nuclear receptor
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.45962959197707404,3.913297228083515,39.99999999999999,1.6020599913279623,0.0391510930713,0.38165228,log10_fold_induction,1.60205999132796,0.1174532792139,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.7460109549562454,20,cell cycle
BSK_4H_VCAM1_down,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.11139444330381384,1.406828622484848,39.99999999999999,1.6020599913279623,0.0228833401839,0.08783517299999999,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.6020599913279623,1.6020599913279623,1.4112498899029993,20,cell adhesion molecules
BSK_CASM3C_LDLR_down,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",NP_000518.1,LDLR,low density lipoprotein receptor,https://www.ncbi.nlm.nih.gov/gene/3949,"[57,57]",,Active,0.10594557599951618,1.3380134979916019,39.99999999999999,1.6020599913279623,0.024506084431499996,0.08569022300000001,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,-0.3083286799784106,20,misc protein
BSK_CASM3C_Thrombomodulin_up,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000352.1,THBD,thrombomodulin,https://www.ncbi.nlm.nih.gov/gene/7056,,,Active,0.2583381775811052,2.57605125125093,1,0,0.0334281881304,0.208239045,log10_fold_induction,1.60205999132796,0.10028456439120001,"[""Less than 50% efficacy""]",0,0,-3.627897279691686,20,gpcr
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,0.16869892436494496,2.0856387841839603,40.000000000000014,1.6020599913279625,0.0269619913164,0.1686896,log10_fold_induction,1.60205999132796,0.0808859739492,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.9407812640698676,20,cytokine
BSK_hDFCGF_MCSF_down,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3,CSF1,colony stimulating factor 1 (macrophage),https://www.ncbi.nlm.nih.gov/gene/1435,,,Active,0.2663731079841841,2.4911439416782053,40.000000000000014,1.6020599913279625,0.0356426758443,0.20900273,log10_fold_induction,1.60205999132796,0.10692802753289998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,-0.05467490699307942,20,cytokine
BSK_hDFCGF_PAI1_down,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",https://www.ncbi.nlm.nih.gov/gene/5054,,,Active,0.21672803909123892,1.3084453901904405,40.000000000000014,1.6020599913279625,0.055212605920499994,0.216691985,log10_fold_induction,1.60205999132796,0.1656378177615,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.0115277721283775,20,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.20904143786054535,1.542700464224133,40.000000000000014,1.6020599913279625,0.0451678604517,0.209009875,log10_fold_induction,1.60205999132796,0.1355035813551,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0062795591309703,20,cell cycle
BSK_hDFCGF_VCAM1_down,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.2433016198131695,1.7218862392553191,40.000000000000014,1.6020599913279625,0.04709982465089999,0.19199286999999998,log10_fold_induction,1.60205999132796,0.14129947395269998,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.6747808858769091,20,cell adhesion molecules
BSK_KF3CT_TIMP2_down,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",,TIMP2,TIMP metallopeptidase inhibitor 2,https://www.ncbi.nlm.nih.gov/gene/7077,,,Active,0.12101317310794532,1.3163413709095222,40.000000000000014,1.6020599913279625,0.030643817220029995,0.12100377500000001,log10_fold_induction,1.60205999132796,0.09193145166008998,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.969335065406074,20,protease inhibitor
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.21166053590139416,1.5334536075062088,40.000000000000014,1.6020599913279625,0.0460095510042,0.158981125,log10_fold_induction,1.60205999132796,0.13802865301259998,"[""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.733454634860156,20,cytokine
BSK_LPS_PGE2_down,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000947.2,PTGER2,"prostaglandin E receptor 2 (subtype EP2), 53kDa",https://www.ncbi.nlm.nih.gov/gene/5732,,,Active,0.4828429089990848,3.4251606289243166,1,0,0.04698980683529999,0.48858377499999994,log10_fold_induction,1.60205999132796,0.14096942050589997,"[""Less than 50% efficacy""]",0,0,-1.8933540777384374,20,gpcr
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.09061453571174362,1.1443939093512379,40.000000000000014,1.6020599913279625,0.0224178208338,0.09059577499999999,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active""]",1.6020599913279625,1.6020599913279625,1.0027822052169064,20,cell adhesion molecules
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.154362827782718,1.5482958039480395,40.000000000000014,1.6020599913279625,0.0332328459435,0.11986055,log10_fold_induction,1.60205999132796,0.09969853783049999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.9115221129963949,20,cytokine
BSK_SAg_Eselectin_up,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.15554490651861724,1.3554348069735527,40.000000000000014,1.6020599913279625,0.038252154885,0.12380353,log10_fold_induction,1.60205999132796,0.114756464655,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.4088115033500168,20,cell adhesion molecules
BSK_SAg_PBMCCytotoxicity_down,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,0.16626986390550408,2.099864200236233,4,0.6020599913279624,0.0217234984974,0.16204633499999999,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",0.6020599913279624,0.6020599913279624,-0.5399190779956948,20,cell cycle
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.25669361987450584,2.1448375333653287,40.000000000000014,1.6020599913279625,0.0398932500141,0.19450554,log10_fold_induction,1.60205999132796,0.1196797500423,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.8704204145550536,20,cell cycle
CCTE_Deisenroth_5AR NBTE_ratio_dn,"Data from the assay component CCTE_Deisenroth_5AR NBTE_ratio was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Deisenroth_5AR NBTE_ratio_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in 5alpha-reductase catalytic function. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is 5-alpha reductase.",, , , ,,,Active,0.6572470900457208,4.3693832140317985,32.76898417642363,1.5154629786600164,0.05014034077968132,0.5476521692234272,fold_induction,2,0.15042102233904395,"[""Less than 50% efficacy""]",1.113520337340206,1.113520337340206,0.7884220192594018,100,misc protein
CCTE_Deisenroth_AIME_384WELL_LUC_Active_up,"CCTE_Deisenroth_AIME_384WELL_LUC_Active_up is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism positive mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_LUC_Active_up, was analyzed in the positive fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,80.005071632101,5.41919214899936,64.15528389423422,1.80723243111791,1.47632837944072,60.2148166813658,percent_activity,2.30102999566398,14.7632837944072,,1.17086151025647,0.592281411699123,0.866256403881817,100,nuclear receptor
CCTE_Deisenroth_AIME_384WELL_LUC_Inactive_up,"CCTE_Deisenroth_AIME_384WELL_LUC_Inactive_up is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates reporter induction in metabolism negative mode. Using a type of inducible reporter in VM7Luc cells, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to xenobiotic metabolism and the gene ESR1. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_LUC_Inactive_up, was analyzed in the positive fitting direction relative to 17beta-estradiol as the positive control in the ERTA assay. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,66.0814495399603,2.9668152174367024,47.36393437885111,1.67544777074306,2.22735306033161,49.0616621983914,percent_activity,2,22.2735306033161,,1.32886204779553,0.555957749863713,0.549621169865695,100,nuclear receptor
CCTE_Deisenroth_AIME_384WELL_LUC_Shift_up,"CCTE_Deisenroth_AIME_384WELL_LUC_Shift_up is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively.                                                                                                                                                                                                                                                                                      This endpoint evaluates the shift in metabolism-dependent changes between positive (active) and negative (inactive) assay modes. The metabolic curve shift response is defined as the pairwise difference between the positive (AEID 2488) and negative (AEID 2490) normalized response values at each concentration for a given chemical across replicate experiments. The pairwise differences form the basis for a concentration-response curve. Standard curve fit analysis identfiied chemicals where the calculated shift was greater than the shift-derived baseline cutoff. A positive hit designation in this endpoint indicates a significant shift trend in the positive direction for bioactivation. ",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,12.5989552592201,1.2683098591826596,111.75261790565594,2.04825770566226,3.31121903899711,12.1775232557326,percent_activity,2.30102999566398,9.93365711699133,"[""Only highest conc above baseline, active""]",2.25258613985728,2.25258613985728,1.707005731017,100,nuclear receptor
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,50.1412677195117,2.5070633859755853,12.252254273036723,1.08821600121247,1.53481347591287,50,percent_activity,1.47712125471966,20,,1.05148287369464,0.882995211625134,0.891438294395751,20,malformation
CCTE_Shafer_MEA_acute_burst_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,69.94683205827116,1.9667744658306388,35.834067974922974,1.5542961131836288,11.854745468359216,49.44161967598626,percent_activity,1.60205999132796,35.56423640507765,"[""Only one conc above baseline, active""]",1.5561304687316828,1.5561304687316828,1.4350156709926547,20,neuroactivity
CCTE_Shafer_MEA_acute_burst_number_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.99999990561147,1.4642581156465502,4.0445595807148,0.6068712374244681,27.317588027077427,99.62248523074749,percent_activity,1.60205999132796,81.95276408123229,"[""Only one conc above baseline, active""]",1.255413588202782,1.255413588202782,-1.2502460347332085,20,neuroactivity
CCTE_Shafer_MEA_acute_burst_percentage_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.99999949341415,8.199174131358689,28.702213466987665,1.457915390093953,4.878540105417866,80.04966299796149,percent_activity,1.60205999132796,14.635620316253597,"[""Only one conc above baseline, active""]",1.0546934487719026,1.0546934487719026,1.0090885014824789,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_area_dn,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_area was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_area_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.96384726668504,1.2907151605934353,2.939924364020239,0.4683361573811413,30.9812345200235,99.83101797816396,percent_activity,1.60205999132796,92.9437035600705,"[""Only one conc above baseline, active"",""Borderline active""]",1.5706977218887985,1.5706977218887985,-1.4922545236001168,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_HWHM was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,106.53729787712466,3.4883409314242044,35.37433662306526,1.5486883042597375,10.180321626765236,75.88698546724041,percent_activity,1.60205999132796,30.54096488029571,"[""Only one conc above baseline, active""]",1.4991980652648753,1.4991980652648753,1.429404366613357,20,neuroactivity
CCTE_Shafer_MEA_acute_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.690776695048,1.686494789990322,5.613862214720639,0.7492617492102747,23.65671438880932,99.4137566368439,percent_activity,1.60205999132796,70.97014316642796,"[""Only one conc above baseline, active""]",1.0167732111809147,1.0167732111809147,-0.8133392837379485,20,neuroactivity
CCTE_Shafer_MEA_acute_interburst_interval_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_interburst_interval_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,54.18622211157131,6.053354920732033,14.581033374466022,1.163788304017955,2.9838121626290146,28.930587564711075,percent_activity,0,8.951436487887044,"[""Noisy data""]",-0.4370524476170723,-0.4370524476170723,-1.0073801861190361,20,neuroactivity
CCTE_Shafer_MEA_acute_network_burst_percentage_dn,"Data from the assay component CCTE_Shafer_MEA_acute_network_burst_percentage was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_network_burst_percentage_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,20.760762941972214,3.90346667889754,38.25567939409273,1.5826959191345227,1.772848312348149,13.954507917253078,percent_activity,1.60205999132796,5.3185449370444475,"[""Only one conc above baseline, active"",""Noisy data""]",1.5235981970267267,1.5235981970267267,1.4608736975035854,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,56.133861183250154,2.665927936946754,25.396283499738704,1.4047701664762209,7.018676987388164,36.45544255871368,percent_activity,1.60205999132796,21.056030962164492,"[""Only one conc above baseline, active""]",1.0168454083936616,1.0168454083936616,-0.26526782896215084,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,102.63917860645584,1.6498215186072804,15.184104334406697,1.181389179257442,20.73743077637071,69.66164871688123,percent_activity,1.60205999132796,62.21229232911213,"[""Borderline active"",""Only one conc above baseline, active""]",1.4644050795433157,1.4644050795433157,-0.26122447061048115,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_spike_number_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_spike_number_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,117.30028587324777,2.2509479043688256,24.141832732916725,1.3827702365806993,17.37050209611422,91.0440382812086,percent_activity,1.60205999132796,52.11150628834265,"[""Only one conc above baseline, active""]",1.3450347613002918,1.3450347613002918,1.0124588213009758,20,neuroactivity
CCTE_Shafer_MEA_acute_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_acute_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.69334480397109,1.7250980032166143,5.568695674110754,0.7457534846044728,23.12783478209955,99.41886729979828,percent_activity,1.60205999132796,69.38350434629865,"[""Only one conc above baseline, active""]",0.9758597832607289,0.9758597832607289,-0.8271121015302595,20,neuroactivity
CCTE_Shafer_MEA_acute_synchrony_index_dn,"Data from the assay component CCTE_Shafer_MEA_acute_synchrony_index was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_synchrony_index_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,84.6810284583954,8.189965271224372,114.2155647789482,2.0577252916243465,3.446535919426672,24.999683811704422,percent_activity,1.60205999132796,10.339607758280016,"[""Only one conc above baseline, active"",""Noisy data""]",1.0573464891152073,1.0573464891152073,0.9434797852819605,20,neuroactivity
CCTE_Simmons_AUR_TPO_dn,"Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",P14650.1,Tpo,thyroid peroxidase,https://www.ncbi.nlm.nih.gov/gene/54314,,,Active,85.5979352728493,4.279896763642465,13.679196254202651,1.13606058037976,5.55295187687267,84.4103581010148,percent_activity,1.95424250943932,20,,0.979491628309446,0.948849170383574,0.846438009829545,20,oxidoreductase
CCTE_Simmons_CellTiterGLO_HEK293T,"Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,46.5063158575788,2.32531579287894,28.80705059363457,1.45949879536892,5.60777764752233,29.9563039681501,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.23621746575738,1.00936428137003,-0.282371937979816,20,cell cycle
CCTE_Simmons_GUA_TPO_dn,"Data from the assay component CCTE_Simmons_GUA_TPO was analyzed at the endpoint, CCTE_Simmons_GUA_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene TPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",,TPO,thyroid peroxidase,https://www.ncbi.nlm.nih.gov/gene/445522,,,Active,34.7017189071793,1.7350859453589649,147.061950280907,2.16750032112586,3.7084553570984,25.6744186046512,percent_activity,2.69897000433602,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",2.33069442260439,1.76927335316605,1.00242058386087,100,oxidoreductase
CEETOX_H295R_11DCORT_dn,"Data from the assay component CEETOX_H295R_11DCORT was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_11DCORT_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.","NP_000167.1|NP_000892.2","NR3C1 | NR3C2","nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) , nuclear receptor subfamily 3, group C, member 2","https://www.ncbi.nlm.nih.gov/gene/2908 , https://www.ncbi.nlm.nih.gov/gene/4306",,,Active,1.46742672425595,2.465444183545914,13.66657721127348,1.13565975930904,0.0991996177977032,1.21808207252977,log2_fold_induction,1.69897000433602,0.595197706786219,,0.994727399388154,0.630849603920148,0.325367351113106,50,steroid hormone
CEETOX_H295R_ANDR_dn,"Data from the assay component CEETOX_H295R_ANDR was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ANDR_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,2.1446577982766,2.845146382393504,28.217717302823072,1.4505218782034,0.125632539890173,1.75376030630843,log2_fold_induction,1.69897000433602,0.753795239341038,,1.34913495786104,1.19472108600537,1.08685083030482,50,steroid hormone
CEETOX_H295R_DOC_dn,"Data from the assay component CEETOX_H295R_DOC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_DOC_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.","NP_000167.1|NP_000892.2","NR3C1 | NR3C2","nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) , nuclear receptor subfamily 3, group C, member 2","https://www.ncbi.nlm.nih.gov/gene/2908 , https://www.ncbi.nlm.nih.gov/gene/4306",,,Active,1.16112959829577,1.3307650163096416,5.499220349126509,0.74030112184454,0.145421315817738,1.02331601799072,log2_fold_induction,1.30102999566398,0.872527894906428,"[""Borderline active"",""Borderline active""]",1.05458957347638,0.596063864663726,0.116118778768325,50,steroid hormone
CEETOX_H295R_ESTRONE_up,"Data from the assay component CEETOX_H295R_ESTRONE was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ESTRONE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Estrone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is estrogens.","NP_000116.2|NP_001428.1","ESR1 | ESR2","estrogen receptor 1 , estrogen receptor 2 (ER beta)","https://www.ncbi.nlm.nih.gov/gene/2099 , https://www.ncbi.nlm.nih.gov/gene/2100",,,Active,1.37252056919976,1.5075848293995153,11.916897025647502,1.0761631866063,0.151735029259398,1.24696826286323,log2_fold_induction,1.69897000433602,0.910410175556388,,1.2798980057106,0.865634529352199,0.415999775516524,50,steroid hormone
CEETOX_H295R_OHPREG_dn,"Data from the assay component CEETOX_H295R_OHPREG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPREG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,1.00769037553274,1.306202365237867,4.583037348724175,0.661153396472088,0.12857762349216,0.982332020747375,log2_fold_induction,1.30102999566398,0.77146574095296,,0.914537684533812,0.558874132905465,0.190736904752438,50,steroid hormone
CEETOX_H295R_OHPROG_dn,"Data from the assay component CEETOX_H295R_OHPROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPROG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,1.57421821360041,1.7400971952334778,22.199095232708018,1.34633527429525,0.150778762810161,1.57181951523407,log2_fold_induction,1.69897000433602,0.904672576860966,,1.36267433512639,1.29702408950517,1.22705382448914,50,steroid hormone
CEETOX_H295R_PROG_dn,"Data from the assay component CEETOX_H295R_PROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PROG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Progesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,1.4263998160071,1.5593348263232099,2.502482947535768,0.398371126784183,0.152458149882028,1.42599941855622,log2_fold_induction,0.778151250383644,0.914748899292168,,0.429912144161182,0.357613221044024,0.279090813094925,50,steroid hormone
CEETOX_H295R_TESTO_dn,"Data from the assay component CEETOX_H295R_TESTO was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_TESTO_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Testosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.96557449111429,1.9699328300961203,22.484673126109126,1.35188657833674,0.166297928291831,1.96229327646665,log2_fold_induction,1.69897000433602,0.997787569750986,,1.3535438710844,1.29334563614726,1.23260625138023,50,steroid hormone
LTEA_HepaRG_ABCB11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003733.2,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",https://www.ncbi.nlm.nih.gov/gene/8647,"[27,27]",,Active,0.937027973698404,1.6695294412896224,63.7184424054015,1.80426515094882,0.187084246719363,0.64198035285346,log2_fold_induction,2,0.561252740158089,"[""Borderline active"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Borderline active""]",1.90653191539316,1.90653191539316,1.24416003605829,20,transporter
LTEA_HepaRG_ACOX1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_009223.2,ACOX1,"acyl-CoA oxidase 1, palmitoyl",https://www.ncbi.nlm.nih.gov/gene/51,,,Active,0.411974748843154,1.018588351605963,30.426423964338248,1.48325091246934,0.134818855982927,0.40858656681892,log2_fold_induction,2,0.404456567948781,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.91382307558349,1.91382307558349,1.24585781924417,20,oxidase
LTEA_HepaRG_CCND1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_444284.1,CCND1,cyclin D1,https://www.ncbi.nlm.nih.gov/gene/595,,,Active,0.585522922961943,1.493343898249966,37.338492997254036,1.57215678559527,0.130696156379454,0.585304488390605,log2_fold_induction,2,0.392088469138362,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.61051418700285,1.61051418700285,1.45287298411504,20,cell cycle
LTEA_HepaRG_CDKN1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000380.1,CDKN1A,"cyclin-dependent kinase inhibitor 1A (p21, Cip1)",https://www.ncbi.nlm.nih.gov/gene/1026,,,Active,0.59059766930508,1.5168241208937172,36.821407563205824,1.56610038615738,0.129788211471984,0.469842682804055,log2_fold_induction,2,0.389364634415952,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",2.0649430637068,2.0649430637068,-0.0944783337606139,20,cell cycle
LTEA_HepaRG_CFLAR_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003870.4,CFLAR,CASP8 and FADD-like apoptosis regulator,https://www.ncbi.nlm.nih.gov/gene/8837,,,Active,0.552784908997237,1.3036185280815686,29.705151624649243,1.4728317734971,0.141346285253843,0.55275077516885,log2_fold_induction,2,0.424038855761529,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.537541546637,1.537541546637,1.35354997233094,20,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1543,"[57,57]",,Active,5.01256870006605,5.565929553207329,96.01746448839542,1.98235023346779,0.300193564683644,2.9304311348583,log2_fold_induction,2,0.900580694050932,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.89990211987283,1.89990211987283,1.86305984566961,20,cyp
LTEA_HepaRG_CYP1A2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000752.2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",https://www.ncbi.nlm.nih.gov/gene/1544,"[131,131]",,Active,6.99319211876956,7.365186985198059,87.03696550892036,1.93970374120401,0.316497604782422,5.26225809521482,log2_fold_induction,2,0.949492814347266,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83922734507607,1.83922734507607,1.82042342709201,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,2.90135417309833,3.8486844305389387,40.72496436967325,1.60986071301588,0.251285361310856,2.35178694967912,log2_fold_induction,2,0.753856083932568,,1.32334412850258,1.32334412850258,1.00849767079918,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,1.1832760465559,2.1099349521991804,55.099015273826815,1.74114383723718,0.186937207917646,0.872231743168265,log2_fold_induction,2,0.560811623752938,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.70949055614689,1.70949055614689,1.07433246966823,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1571,,,Active,2.44281023333201,5.100584804313504,87.83794122758565,1.94368214809899,0.159642493756543,1.64269303169381,log2_fold_induction,2,0.478927481269629,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64946356887223,1.64946356887223,1.48556384772142,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",https://www.ncbi.nlm.nih.gov/gene/1576,,,Active,1.77148624747957,1.4929333491420622,61.238387317419864,1.78702374524687,0.395526977922934,1.27083208345954,log2_fold_induction,2,1.1865809337688,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.97344581981131,1.97344581981131,1.20797089346923,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2,CYP7A1,"cytochrome P450, family 7, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1581,,,Active,1.03542862134397,1.9277361158996142,46.10640476048545,1.66376125855519,0.179040518530855,0.705890325610598,log2_fold_induction,2,0.537121555592565,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.71705472107101,1.71705472107101,0.102623882620872,20,cyp
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1,FABP1,"fatty acid binding protein 1, liver",https://www.ncbi.nlm.nih.gov/gene/2168,,,Active,1.41411792502657,2.9302430374219064,69.47523378796585,1.84183001687658,0.160864691309103,0.96738194174791,log2_fold_induction,2,0.482594073927309,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.59690244407601,1.59690244407601,1.02351598899813,20,transporter
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4,FASN,fatty acid synthase,https://www.ncbi.nlm.nih.gov/gene/2194,"[58,34,34,58]",,Active,1.35888086904483,3.6972759783950426,82.67884805709825,1.91739441708526,0.122511895873739,0.821710946435776,log2_fold_induction,2,0.367535687621217,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.70516628413398,1.70516628413398,1.44743578066102,20,lyase
LTEA_HepaRG_GADD45B_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_056490.2,GADD45B,"growth arrest and DNA-damage-inducible, beta",https://www.ncbi.nlm.nih.gov/gene/4616,,,Active,0.727728649785154,1.7346241984725415,82.88509000602244,1.91847641341529,0.139843671504558,0.593916517604875,log2_fold_induction,2,0.419531014513674,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.93535644447675,1.93535644447675,1.7982115771473,20,mutagenicity response
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,,IGF1,insulin-like growth factor 1 (somatomedin C),https://www.ncbi.nlm.nih.gov/gene/3479,,,Active,1.05855797425528,2.1746095220223096,65.24005551946907,1.81451432195421,0.162260237763032,0.73693429044607,log2_fold_induction,2,0.486780713289096,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.77599475891777,1.77599475891777,1.2886142672099,20,growth factor
LTEA_HepaRG_IL6R_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000556.1,IL6R,interleukin 6 receptor,https://www.ncbi.nlm.nih.gov/gene/3570,,,Active,0.779161753434428,1.9898740867781932,190.27553719288355,2.27938295673129,0.130521114981027,0.457942868306355,log2_fold_induction,2,0.391563344943081,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",2.2888170599624,2.2888170599624,0.242656413922428,20,cytokine receptor
LTEA_HepaRG_KRT19_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002267.2,KRT19,keratin 19,https://www.ncbi.nlm.nih.gov/gene/3880,,,Active,1.73693580735707,3.206528805881193,50.94268911211519,1.70708186633879,0.180562420456175,1.33897301772374,log2_fold_induction,2,0.541687261368525,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.46026440516304,1.46026440516304,1.02184144092823,20,filaments
LTEA_HepaRG_LPL_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000228.1,LPL,lipoprotein lipase,https://www.ncbi.nlm.nih.gov/gene/4023,,,Active,0.65821344577092,1.6689407734391717,34.0199205100643,1.53173329451815,0.131463312189033,0.658087239454,log2_fold_induction,2,0.394389936567099,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55355986905599,1.55355986905599,1.41245280030187,20,esterase
LTEA_HepaRG_PEG10_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001165908.1,PEG10,paternally expressed 10,https://www.ncbi.nlm.nih.gov/gene/23089,,,Active,1.86956138987234,2.7511853678718348,69.75332698686928,1.84356492674965,0.226515863756396,1.42699446933778,log2_fold_induction,2,0.679547591269188,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.76824167191204,1.76824167191204,1.5481799534318,20,dna binding
LTEA_HepaRG_STAT3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_644805.1,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),https://www.ncbi.nlm.nih.gov/gene/6774,,,Active,0.575981042355508,1.2627484630547758,52.225405764266554,1.71788182290792,0.152044279919936,0.47729215051427,log2_fold_induction,2,0.456132839759808,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.98154403735726,1.98154403735726,1.28443632615229,20,dna binding
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1,THRSP,thyroid hormone responsive,https://www.ncbi.nlm.nih.gov/gene/7069,,,Active,1.47855231341542,1.5214222560019428,42.93364601697056,1.63279777126105,0.323940818661091,1.21403818184122,log2_fold_induction,2,0.971822455983273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.796803058539,1.796803058539,1.07942067778855,20,growth factor
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",https://www.ncbi.nlm.nih.gov/gene/54658,,,Active,2.41516321100285,3.6464297832117074,69.5297935849292,1.84217094008518,0.220778803248623,1.61254790548922,log2_fold_induction,2,0.662336409745869,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.50979051399795,1.50979051399795,1.09175393800771,20,transferase
NVS_ADME_hCYP1A2,"Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000752.2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",https://www.ncbi.nlm.nih.gov/gene/1544,"[131,131]",,Active,102.698518120931,5.13492590604655,1.2358975626807551,0.0919824757640191,1.22140528143636,101.634020095402,percent_activity,1.30102999566398,20,,-0.390747996408208,-1.02920469095466,-0.655245502890933,20,cyp
NVS_ADME_hCYP2C19,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,94.09843868695,4.7049219343475,5.975962003823517,0.7764078274984,2.60299124232151,78.415365575019,percent_activity,1.30102999566398,20,,0.259783284862641,-0.171284149866747,-0.0903348734698542,20,cyp
NVS_ADME_hCYP2C9,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000762.2,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",https://www.ncbi.nlm.nih.gov/gene/1559,,,Active,69.1786074642253,3.4589303732112646,7.538864278813779,0.877305924835939,2.17335298616219,57.648839556004,percent_activity,1.30102999566398,20,,0.620904321704852,0.232454557572915,0.251146823392731,20,cyp
NVS_ENZ_rMAOAC,"Data from the assay component NVS_ENZ_rMAOAC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",P21396.1,Maoa,monoamine oxidase A,https://www.ncbi.nlm.nih.gov/gene/29253,,,Active,85.0347050774799,4.251735253873995,13.57407161600674,1.13271013617374,3.12466620760733,70.862254232858,percent_activity,1.69897000433602,20,,0.674489105031014,0.321210063687895,0.278890518689637,20,oxidoreductase
NVS_OR_gSIGMA_NonSelective,"Data from the assay component NVS_OR_gSIGMA_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_gSIGMA_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sigmar1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""chaperone"".",NP_001166463.1,Sigmar1,sigma non-opioid intracellular receptor 1,https://www.ncbi.nlm.nih.gov/gene/100135589,,,Active,35.1164323055305,1.6535324007720846,40.932444271665354,1.61206767921652,3.53953676072849,29.2636948602994,percent_activity,1.69897000433602,21.2372205643709,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6351592894709,1.56668520360618,1.4927873617276,20,misc protein
NVS_TR_hNET,"Data from the assay component NVS_TR_hNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",NP_001034.1,SLC6A2,"solute carrier family 6 (neurotransmitter transporter), member 2",https://www.ncbi.nlm.nih.gov/gene/6530,,,Active,58.4753363211615,2.2511583134500963,9.468572440486614,0.976284506146502,4.32927765614309,48.729446935725,percent_activity,1.69897000433602,25.9756659368585,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.872166079249129,0.393856094179305,-0.0446991074442831,20,transporter
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,79.6825452155797,2.480264171439116,11.166476900364566,1.04791617185526,5.35443940025589,77.23663467325,percent_activity,1.95424250943932,32.1266364015353,,0.932167276458642,0.641731025834372,0.399489394245054,20,nuclear receptor
TOX21_CAR_Agonist,"Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_001070948.1,NR1I3,"nuclear receptor subfamily 1, group I, member 3",https://www.ncbi.nlm.nih.gov/gene/9970,,,Active,43.1472504215525,2.157362521077625,64.73973029157183,1.81117088578132,0.83822208889671,26.4984254954,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.76905732342068,1.00937083480951,1.17800683725131,20,nuclear receptor
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,27.0598912272337,1.1274664296713344,27.273316906581606,1.43573795886668,4.0001030208237,27.2026377441,percent_activity,1.69897000433602,24.0006181249422,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.54756370419714,1.42341037289776,1.31645740731321,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,"RAD54L | XRCC6P1","RAD54 like (S. cerevisiae) , X-ray repair cross complementing 6 pseudogene 1","https://www.ncbi.nlm.nih.gov/gene/8438 , https://www.ncbi.nlm.nih.gov/gene/387703",,,Active,48.9255503302626,2.268285833896248,22.922141827699715,1.36025519534125,3.59489896137582,48.6147808086,percent_activity,1.69897000433602,21.5693937682549,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.34735252289689,1.29167957193434,1.24096998421252,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,REV3L,"REV3 like, DNA directed polymerase zeta catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/5980,,,Active,44.3976093621901,1.6944349091049977,31.994466315228824,1.50507487030182,4.36700254498032,42.59945813225,percent_activity,1.95424250943932,26.2020152698819,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.55942986432268,1.37527218878286,1.17756112541623,20,cell cycle
TOX21_ERa_LUC_VM7_Agonist,"Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,200,29,165,53,52,167,112,30,67,29,165,53,52,30,67,112,167]",[1181],Active,44.6441843732286,2.23220921866143,39.720177288714815,1.59901117827598,2.77515618820713,24.735823831,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.49255458650753,0.848026862321124,0.478803675910084,20,nuclear receptor
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3,ESRRA,estrogen-related receptor alpha,https://www.ncbi.nlm.nih.gov/gene/2101,,,Active,128.695068473179,6.090358590985461,282.6309704372835,2.4512197497031,3.52182515338437,35.1975813585,percent_activity,1.95424250943932,21.1309509203062,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.64019819575911,1.24805958429509,1.35618894715594,20,nuclear receptor
TOX21_H2AX_HTRF_CHO_Agonist_ratio,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.",NP_002096.1,H2AFX,"H2A histone family, member X",https://www.ncbi.nlm.nih.gov/gene/3014,,,Active,34.9240535241922,1.7462026762096101,46.24107459739941,1.66502791810923,1.1538473582706,23.9532559649,percent_activity,1.90308998699194,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.74580745564189,1.0560365730185,1.05875664298406,20,dna binding
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,100.223922896063,2.5922092676498485,9.795940730749795,0.991046148810151,6.44391923052108,92.28621655965,percent_activity,1.95424250943932,38.6635153831265,,0.870235687451986,0.619264116722507,0.420341229702728,20,cell morphology
TOX21_MMP_viability,"TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,20.8886698964656,1.04443349482328,10.341742446524291,1.01459371778665,3.32276785161468,21.5246478278,percent_activity,1.69897000433602,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.52291888247911,0.999702094747907,0.655894289062131,20,cell cycle
TOX21_PR_BLA_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,81.6447660736735,1.9652130377552368,22.431887878786718,1.35086582555966,6.92416585421295,74.75658912015,percent_activity,1.95424250943932,41.5449951252777,,1.35789426731598,1.13744096719188,0.914700369218402,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,98.2003713555996,4.91001856777998,20.5005854234124,1.31176626313026,2.51198214229767,77.4750565259,percent_activity,1.95424250943932,20,,0.907605242294731,0.574463988780532,0.660497399964263,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,,,Active,192.160752369174,9.608037618458699,180.119222759579,2.25556006425162,1.80636679455099,63.6587234951,percent_activity,1.95424250943932,20,,1.54730608996228,1.09093934537791,1.53265596202855,20,nuclear receptor
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,81.3113402211847,3.3490679847364477,11.131867083125819,1.04656801212395,4.04646609105207,67.759450219,percent_activity,1.60205999132796,24.2787965463124,,0.535109767918955,0.00442626166379445,-0.269314993555983,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,76.9210224110322,3.1909158863010814,11.948596582993478,1.07731689841768,4.0177086637968,64.1008521316,percent_activity,1.60205999132796,24.1062519827808,,0.557335305753716,-0.0384832367065082,-0.379380389497469,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,72.4150961409848,2.9514819932866003,15.642824036805724,1.19431516003371,4.08919407864135,60.3459134644,percent_activity,1.60205999132796,24.5351644718481,,0.723698096328702,0.0752334765921592,-0.35230205085669,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,67.7789713990593,2.6979498157558015,16.02947526004888,1.20491930554845,4.18706647811088,56.4824762354,percent_activity,1.60205999132796,25.1223988686653,,0.874091524886911,0.279668878058449,-0.168094230659744,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,62.1167227463556,2.494109228283721,15.425808727329434,1.18824794201546,4.15089564121323,51.7639356304,percent_activity,1.60205999132796,24.9053738472794,,0.97420182621878,0.450820101969831,0.0169602237541133,20,cell cycle
TOX21_TSHR_HTRF_Agonist_ratio,"Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",,TSHR,thyroid stimulating hormone receptor,https://www.ncbi.nlm.nih.gov/gene/7253,,,Active,67.7119179294258,2.4315030342999413,41.946625738101005,1.62269703114178,4.64129367543786,66.24832907635,percent_activity,1.95424250943932,27.8477620526272,,1.59006177217416,1.49974830106686,1.42280296174597,20,gpcr
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,45.4728175926044,1.1973591783994746,8.665844560869104,0.937810894834261,12.6591971211703,59.3346024572513,percent_activity,2,37.9775913635109,"[""Borderline active"",""Borderline active""]",1.02590373272983,1.02590373272983,0.818530575789898,19.99970054626465,nuclear receptor